HUMA
NASDAQHumacyte Inc.
News25/Ratings11
Price$0.70-0.31 (-30.61%)
2026-05-212026-08-25
News · 26 weeks68+175%
2026-03-012026-08-23
Mix3690d
- Insider13(36%)
- Other11(31%)
- SEC Filings7(19%)
- Offering3(8%)
- Leadership1(3%)
- Earnings1(3%)
Latest news
25 items- SECSEC Form 25-NSE filed by Humacyte Inc.25-NSE - Humacyte, Inc. (0001818382) (Subject)
- PRHumacyte Confirms Plans for ATEV Supplemental BLA Filing for Dialysis Access Following FDA Discussions– Supplemental Biologics License Application (BLA) expected to be filed with the Food and Drug Administration (FDA) in November 2026 – – Supplemental BLA will be supported by results from three Phase 3 studies of ATEV, including results from V012 dialysis access study in women – – The V012 dialysis access study found that women who received Humacyte's ATEV experienced an average of three more months without a dialysis catheter than women who received AV fistula, the current standard of care – DURHAM, N.C., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues
- INSIDERDirector Jones Keith Anthony bought $6,930 worth of shares (10,000 units at $0.69), increasing direct ownership by 33% to 40,000 units (SEC Form 4)4 - Humacyte, Inc. (0001818382) (Issuer)
- INSIDERDirector Jones Keith Anthony bought $17,820 worth of shares (30,000 units at $0.59) (SEC Form 4)4 - Humacyte, Inc. (0001818382) (Issuer)
- PRHumacyte Announces Lancet Digital Health Publication of V007 Phase 3 Hemodialysis Access Trial Results– Phase 3 results highlight benefits of ATEV for patients at higher risk of fistula failure, including all women and men with obesity and diabetes – – Publication provides peer-reviewed validation for V007 Phase 3 data, and complements recent release of Phase 3 V012 data showing ATEV outperformed standard of care for women on dialysis – DURHAM, N.C., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the publication of one-year results from the V007 Phase 3 clinical trial of the acellular tissue engineered vessel (ATEV) in art
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Humacyte Inc.SCHEDULE 13D/A - Humacyte, Inc. (0001818382) (Subject)
- PRBoard-Certified Vascular and Endovascular Surgeon Performs First Commercial Symvess® Implantation; Cites Bioengineered Blood Vessel as “Revolutionary Advancement”– Jeromy Brink, MD, Mayo Clinic–trained vascular surgeon in Phoenix, is the first surgeon in Arizona to implant Symvess, the first and only FDA-approved bioengineered human blood vessel – – Symvess is available off-the-shelf in the operating room, sparing surgeons the time required to harvest a vein from a patient facing imminent limb loss – DURHAM, N.C., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology company that develops bioengineered human tissues, today announced that Symvess, acellular tissue engineered vessel-tyod, is now being used by surgeons in Arizona. The first post-Biologics License Application (BLA) approval implants in the s
- SECSEC Form 10-Q filed by Humacyte Inc.10-Q - Humacyte, Inc. (0001818382) (Filer)
- SECHumacyte Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Humacyte, Inc. (0001818382) (Filer)
- PRHumacyte Announces Second Quarter 2026 Financial Results and Provides Business Update– Breakthrough results from V012 dialysis access Phase 3 study, where ATEV was observed to outperform AV fistula; supplemental Biologic License Application (sBLA) for dialysis access to be filed with the Food and Drug Administration (FDA) during the second half of 2026 – – FDA accepted IND for first-in-human clinical study of CTEV for CABG with Phase 2a study expected to start Q3 2026 – – Second quarter sales of Symvess® were $0.4 million in 2026 compared to $0.1 million in 2025 – – Conference call today at 8:00 am ET – DURHAM, N.C., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable,
- PRHumacyte To Announce 2026 Second Quarter Financial Results and Provide Business Update on August 12, 2026DURHAM, N.C., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that the Company will release its financial results for the three months and six months ended June 30, 2026, on Wednesday, August 12, 2026. Management will host a webcast and conference call at 8:00 a.m. Eastern Time to provide a corporate and financial update. TitleHumacyte 2025 Second Quarter Financial Results and Corporate UpdateDateAugust 12, 2026Time8:00 a.m. Eastern TimeConference Details1-877-704-4453 (U.S. Investors)1-201-389-0920 (International Investors)1
- SECHumacyte Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - Humacyte, Inc. (0001818382) (Filer)
- PRHumacyte Announces FDA Acceptance of IND for First-In-Human Clinical Study of CTEV for Coronary Artery Bypass Grafting– Phase 2a study of CTEV in coronary artery bypass grafting (CABG) is expected to start this quarter – – Progression of CTEV into human study supported by positive preclinical results presented at multiple scientific meetings and in a recent publication – DURHAM, N.C., July 27, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced that the Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for a first-in-human clinical study of the coronary tissue engineered vessel (CTEV) in coronary artery bypass grafti
- PRHumacyte Appoints Key Nephrologists as Advisors to Prepare for Planned Commercialization of the ATEV in Dialysis Access- Dr. Robert J. Kossmann has served as a prominent advocate for kidney disease patients in multiple roles including Executive Vice President and Chief Medical Officer for Fresenius Medical Care North America - - Dr. Prabir Roy-Chaudhury is the Immediate Past President of the American Society of Nephrology, serves as the Drs Ronald and Katherine Falk Eminent Professor at UNC, and is the Co-Director of the UNC Kidney Center - DURHAM, N.C., July 14, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that Robert J. (Rob) Kossmann, MD, FACP
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Humacyte Inc.SCHEDULE 13D/A - Humacyte, Inc. (0001818382) (Subject)
- SECSEC Form SCHEDULE 13G filed by Humacyte Inc.SCHEDULE 13G - Humacyte, Inc. (0001818382) (Subject)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Humacyte Inc.SCHEDULE 13D/A - Humacyte, Inc. (0001818382) (Subject)
- PRHumacyte's Bioengineered Blood Vessel Outperforms the Standard of Care for Women on Dialysis in Phase 3 Results Presented at the Society for Vascular Surgery Vascular Annual Meeting– Positive results from the V012 Phase 3 study were presented at the Society for Vascular Surgery's Vascular Annual Meeting in Boston – – Women who received Humacyte's ATEV experienced an average of three more months without a dialysis catheter than women who received AV fistula, the current standard of care – – Company to hold investor event today, June 15th, at 5:00 p.m. ET – DURHAM, N.C., June 15, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology company that develops bioengineered human tissues, presented detailed results from its V012 Phase 3 study showing that the Company's bioengineered blood vessel – the acellular tissue engineered vessel, o
- INSIDERSEC Form 4 filed by Director Windham-Bannister Susan Richards4 - Humacyte, Inc. (0001818382) (Issuer)
- INSIDERSEC Form 4 filed by Director Constantino Michael T.4 - Humacyte, Inc. (0001818382) (Issuer)
- INSIDERSEC Form 4 filed by Director Wallace Max N.4 - Humacyte, Inc. (0001818382) (Issuer)
- INSIDERSEC Form 4 filed by President, CEO and Director Niklason Laura E4 - Humacyte, Inc. (0001818382) (Issuer)
- INSIDERSEC Form 4 filed by Director Sebelius Kathleen4 - Humacyte, Inc. (0001818382) (Issuer)
- INSIDERSEC Form 4 filed by Director Jones Keith Anthony4 - Humacyte, Inc. (0001818382) (Issuer)
- INSIDERSEC Form 4 filed by Director Green Charles Bruce4 - Humacyte, Inc. (0001818382) (Issuer)
HUMA FAQ
6 questionsWhere does HUMA stock trade?
Humacyte Inc. (HUMA) is listed on NASDAQ.What sector and industry is HUMA in?
Humacyte Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Humacyte Inc. go public?
Humacyte Inc. (HUMA) completed its IPO in 2020.What are analysts saying about HUMA?
Humacyte Inc. has had 8 recent analyst actions on file. The most recent action was from Barclays: Overweight with a $350.00 price target on 2025-08-27. Recent price targets range from $350.00 to $1700.00.What companies are similar to HUMA?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare HUMA side-by-side with any of them on Quantisnow.How can I track HUMA on Quantisnow?
Quantisnow aggregates Humacyte Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow HUMA to receive live email and push alerts on every new disclosure.